Drugs / Recombinant human Neuregulin
Recombinant human Neuregulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04468529 | Dec 2020 → Apr 2022 | systolic heart failure | Zensun Sci. & Tech. Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-09-04 | Zensun Sci. & Tech. Co., Ltd. | Regulatory ZENSUN ANNOUNCES THE INVESTIGATION OF NEUCARDIN FOR CHRONIC HEART FAILURE RECEIVES FAST TRACK DESIGNATION FROM THE US FDA zensun.com ↗ |
| 2017-02-07 | Zensun Sci. & Tech. Co., Ltd. | Results Exciting results from the Neucardin™ Phase III clinical trial (Interim Analysis) zensun.com ↗
The results reveal that based on the clinical standard therapy, Neucardin™ reduced one-year all-cause mortality (the primary endpoint) by 17% compared with placebo in mild to moderate CHF patients. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-03-23 | Zensun Sci. & Tech. Co., Ltd. | Zensun is Collaborating with The Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. to Conduct a Preclinical Study of Neucardin® (recombinant human Neuregulin-1) for The Treatment of Schwannomas zensun.com ↗ |
| 2019-09-04 | Zensun Sci. & Tech. Co., Ltd. | ZENSUN ANNOUNCES THE INVESTIGATION OF NEUCARDIN FOR CHRONIC HEART FAILURE RECEIVES FAST TRACK DESIGNATION FROM THE US FDA zensun.com ↗ |
| 2017-02-07 | Zensun Sci. & Tech. Co., Ltd. | Exciting results from the Neucardin™ Phase III clinical trial (Interim Analysis) zensun.com ↗ |
| 2015-03-09 | Zensun Sci. & Tech. Co., Ltd. | An International Multi-center Phase III Clinical Trial of Recombinant Human Neuregulin-1 is going to zensun.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human Neuregulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04468529 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human Neuregulin for injection” NCT04468529 ↗ |
| Route | Intravenous | “i.v. drip” NCT04468529 ↗ |